Holen Sie sich die Stockscreener-App
2.44
2.79%
-0.07
Handel nachbörslich:
2.48
0.04
+1.64%
Schlusskurs vom Vortag:
$2.51
Offen:
$2.48
24-Stunden-Volumen:
1.62M
Relative Volume:
0.67
Marktkapitalisierung:
$204.26M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.8472
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-22.54%
1M Leistung:
+8.44%
6M Leistung:
+86.26%
1J Leistung:
-52.53%
1-Tages-Spanne:
$2.37
$2.49
1-Wochen-Bereich:
$2.37
$3.19
52-Wochen-Spanne:
$0.9101
$5.085
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.44 | 210.12M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Is Editas Medicine Inc. a growth stock or a value stockPre Market Picks With High Returns - jammulinksnews.com
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsReal Time Watchlist To Watch Now - jammulinksnews.com
What is the dividend policy of Editas Medicine Inc. stockTop Growth Alerts With Proven Results - jammulinksnews.com
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? - Yahoo Finance
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas MedicinePrimed For An Unlikely Comeback? It's Not Impossible - Seeking Alpha
EDIT SEC FilingsEditas Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Editas Medicine Inc. Flashes Buy Signal on Multi Timeframe ChartChart Driven High Reward Trading Setup Presented - metal.it
Published on: 2025-07-29 18:14:10 - metal.it
Published on: 2025-07-29 11:06:01 - metal.it
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Gene Editing Market Exclusive Report with Detailed Study - openPR.com
What is Editas Medicine Inc. company’s growth strategyFree Stock Index Interpretation - jammulinksnews.com
Does Editas Medicine Inc. stock perform well during market downturnsHigh-velocity capital appreciation - jammulinksnews.com
Why is Editas Medicine Inc. stock attracting strong analyst attentionMaximize returns with smart investment plans - jammulinksnews.com
What catalysts could drive Editas Medicine Inc. stock higher in 2025Invest confidently with daily market forecasts - jammulinksnews.com
Should I hold or sell Editas Medicine Inc. stock in 2025Identify breakout stocks before they peak - jammulinksnews.com
Is Editas Medicine Inc. stock overvalued or undervaluedUnlock daily market insights for better decisions - jammulinksnews.com
What drives Editas Medicine Inc. stock priceTriple-digit profit margins - PrintWeekIndia
Will Editas Medicine Inc. stock split in the near futureConsistent triple-digit returns - jammulinksnews.com
Can Editas Medicine Inc. stock recover from recent declineFree Stock Market Forecast Reports - jammulinksnews.com
What analysts say about Editas Medicine Inc. stockBreakout stock performance - Autocar Professional
What drives Avanos Medical Inc. stock priceExplosive market performance - jammulinksnews.com
Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st
What makes Editas Medicine Inc. stock price move sharplyVerified Return Tips - beatles.ru
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):